This collaboration is recited -- in the morning's press release -- as being six-months old, now. That corresponds to the moment when B + L Chairman Fred Hassan installed Brent Sauders (fellow legacy Schering-Plough alum) as his CEO/President/proxy at B + L. Not surprisingly, the VP of Research at NiCox is a long-time legacy Schering-Plough cohort of both Hassan and Saunders, to boot: ". . .Before joining Nicox, Ennio Ongini held various senior level positions at the Schering-Plough Research Institute, the most recent of which was Director of the research center at the San Raffaele Science Park in Milan. . . ." Cozy.
. . . .Bausch + Lomb has initiated a phase 2b clinical study with BOL-303259-X, previously known as NCX 116. BOL-303259-X is a nitric oxide-donating prostaglandin F2-alpha analog, which lowers intraocular pressure through a dual mechanism of action. It has been developed for the potential treatment of glaucoma and ocular hypertension and was licensed to Bausch + Lomb by NicOx in March 2010. . . .
The primary efficacy endpoint is the reduction in mean diurnal IOP at day 28. Secondary measures will include the reduction of mean diurnal IOP at other time points and the safety of BOL-303259-X, as compared to Xalatan®.
In March 2010, NicOx and Bausch + Lomb signed a worldwide licensing agreement for BOL-303259-X for the treatment of glaucoma and ocular hypertension. Under the terms of the agreement, Bausch + Lomb made an initial license payment to NicOx of $10 million. NicOx stands to receive potential development, regulatory, commercialization and sales success-based milestones, which, over time, could total $169.5 million. NicOx will also receive tiered double-digit royalties on the sales of BOL-303259-X. . . .
Fascinating. NicOx’s pipeline also includes several nitric oxide-donating NMEs, which are the subject of a signifcant research collaboration with Merck.
Very cozy.
No comments:
Post a Comment